...
首页> 外文期刊>Critical care : >Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study
【24h】

Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study

机译:血清神经元特异性烯醇化酶可预测院内心脏骤停后的预后:一项队列研究

获取原文

摘要

IntroductionOutcome after cardiac arrest is mostly determined by the degree of hypoxic brain damage. Patients recovering from cardiopulmonary resuscitation are at great risk of subsequent death or severe neurological damage, including persistent vegetative state. The early definition of prognosis for these patients has ethical and economic implications. The main purpose of this study was to investigate the prognostic value of serum neuron-specific enolase (NSE) in predicting outcomes in patients early after in-hospital cardiac arrest.MethodsForty-five patients resuscitated from in-hospital cardiac arrest were prospectively studied from June 2003 to January 2005. Blood samples were collected, at any time between 12 and 36 hours after the arrest, for NSE measurement. Outcome was evaluated 6 months later with the Glasgow outcome scale (GOS). Patients were divided into two groups: group 1 (unfavorable outcome) included GOS 1 and 2 patients; group 2 (favorable outcome) included GOS 3, 4 and 5 patients. The Mann–Whitney U test, Student's t test and Fisher's exact test were used to compare the groups.ResultsThe Glasgow coma scale scores were 6.1 ± 3 in group 1 and 12.1 ± 3 in group 2 (means ± SD; p < 0.001). The mean time to NSE sampling was 20.2 ± 8.3 hours in group 1 and 28.4 ± 8.7 hours in group 2 (p = 0.013). Two patients were excluded from the analysis because of sample hemolysis. At 6 months, favorable outcome was observed in nine patients (19.6%). Thirty patients (69.8%) died and four (9.3%) remained in a persistent vegetative state. The 34 patients (81.4%) in group 1 had significantly higher NSE levels (median 44.24 ng/ml, range 8.1 to 370) than those in group 2 (25.26 ng/ml, range 9.28 to 55.41; p = 0.034).ConclusionEarly determination of serum NSE levels is a valuable ancillary method for assessing outcome after in-hospital cardiac arrest.
机译:前言心脏骤停后的结果主要取决于缺氧性脑损伤的程度。从心肺复苏中康复的患者极有可能随后死亡或严重的神经系统损害,包括持续的植物生长状态。这些患者的预后的早期定义具有伦理和经济意义。这项研究的主要目的是探讨血清神经元特异性烯醇化酶(NSE)在预测院内心脏骤停后早期患者预后中的预后价值。方法从6月开始对45例院内心脏骤停复苏的患者进行前瞻性研究。 2003年至2005年1月。在逮捕后12到36个小时之间的任何时间收集血液样本用于NSE测量。 6个月后用格拉斯哥结局量表(GOS)评估结局。患者分为两组:第一组(不良结果)包括GOS 1和2例患者;第2组(预后良好)包括GOS 3、4和5例患者。结果采用Mann–Whitney U检验,Student's t检验和Fisher精确检验进行比较。结果格拉斯哥昏迷量表评分在第1组为6.1±3,在第2组为12.1±3(平均值±SD; p <0.001)。第一组的平均NSE采样时间为20.2±8.3小时,第二组的平均时间为28.4±8.7小时(p = 0.013)。由于样本溶血,两名患者被排除在分析之外。在6个月时,有9例患者(19.6%)观察到了良好的预后。 30例患者(69.8%)死亡,而4例(9.3%)仍处于持续的植物状态。第1组的34例患者(81.4%)的NSE水平(中位数44.24 ng / ml,范围8.1至370)显着高于第2组的25.26 ng / ml,范围9.28至55.41; p = 0.034)。血清NSE水平的评估是评估院内心脏骤停后结局的有价值的辅助方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号